Fracture Recovery for Returning to Duty (Teriparatide STRONG)

Stress Fracture Clinical Trial

Official title: Fracture Recovery for Returning to Duty (Teriparatide STRONG)

Status Not yet recruiting

Clinical Trial Summary

FORTEO (teriparatide [rDNA origin]; Eli-Lilly, Indiana, USA) is an injectable synthetic recombinant human parathyroid hormone analog that is commonly used to treat people with osteoporosis. In the current investigation this drug will be tested to evaluate its efficacy to accelerate bone healing and decrease the convalescence time of US Army Basic Trainees who have sustained a diaphyseal tibial stress fracture (DTSF). Investigators from the University of South Carolina will collaborate with military personnel to perform a prospective, randomized, double-blind, placebo-controlled study at Fort Jackson, SC.

Clinical Trial Description

GOALS The project goals are to improve combat readiness of U.S. soldiers and sustain the availability of the military to deploy by, 1) decreasing the number of days not physically ready for duty after diagnosis of a stress fracture of the tibia, 2) decreasing the need for a physical profile or medical board after stress fracture of the tibia, and 3) decreasing the recurrence rates of these injuries.

AIMS AND HYPOTHESES Specific Aim One is to determine the difference in the time from diagnosis to full return to activity for soldiers with diaphyseal tibia stress fracture who receive the teriparatide protocol compared to those who receive a placebo-control self-injection. This aim will be addressed by performing a prospective, longitudinal randomized, placebo-controlled trial in which 183 soldiers with acutely diagnosed diaphyseal tibia stress fractures will randomly receive a 1-month course of daily, self-injected 20 mcg. of teriparatide or daily, self-injected placebo.

• Hypothesis 1.1: Soldiers receiving teriparatide will return to duty 40% more quickly than those receiving placebo as measured in days from diagnosis to return to duty.

• Hypothesis 1.2: Following return to duty soldiers receiving teriparatide will be able to sustain a high daily duty load as measured in metabolic equivalents (METs) on a daily training log.

Specific Aim Two is to determine the long-term effects of the administration of teriparatide. Study participants will be followed for 1-year after the completion of the study drug year to determine the incidence of drug related side effects, injury recurrence and/or additional bone stress injury based on data from the participants' Electronic Medical Record.

• Hypothesis 2.1: Soldiers receiving teriparatide will have a reduced rate of new and/or recurrent bone stress injuries as measured by their need for a military physical profile due to bone stress injuries and/or their medical record diagnosis of a bone stress injury than those treated with placebo.

• Hypothesis 2.2: Soldiers receiving teriparatide will be more likely to complete their first assigned station as measured by a medical discharge board than those treated with placebo.

• Hypothesis 2.3: Soldiers receiving teriparatide will have a high bone mass as measured by DEXA scan age matched t-score than those treated with placebo than those treated with placebo.

RECRUITMENT AND SCREENING OF PARTICIPANTS Soldiers who have pain in the mid-tibia area while in basic training at Ft. Jackson, SC report to Moncrief Medical Clinic where they are medically evaluated by their Primary Care Manager (PCM). The injured soldiers would have further diagnostic testing in the form of anterior-posterior (A-P) and lateral view radiographs of the tibia followed by a radio-nucleotide bone scan if indicated. Soldiers found to have a DTSF report to the physical therapy department for further evaluation and treatment. The physical therapist will notify the embedded research nurse coordinator of a new soldier who has a DSTF and will initiate a pre-screen for study participation.

If the DTSF and resulting functional limitation is so severe to require convalescent leave, the research nurse coordinator will be notified and will approach the patient to provide general information about the study and invite the patient to learn more about potential participation. For patients who are interested in participating, the research nurse coordinator will initiate the informed consent process. All study risks and potential benefits will be discussed with the patient. Informed consent information and discussion will include information about the need to self-administer the study medication. Once a fully executed informed consent document has been signed, the research nurse coordinator will initiate the study screening visit that will require participants to complete a medical questionnaire to assess eligibility based on their personal medical history. An initial blood draw will be obtained that will assess suitability for initiating therapy with teriparatide, including lab values within the following ranges:

Total serum calcium (normal range 8.5-10.2 mg/dL) Total serum alkaline phosphatase: (normal range 44 to 147 IU/L) 25-hydroxyvitamin D: (normal range 20 and 40 ng/mL) Parathyroid Hormone: (normal - 10-65 pig/mL or 10-65 ng/L) Creatinine clearance: (normal 88-128 mL/min for healthy women or 97-137 mL/min for healthy men) Serum qualitative urine pregnancy test (females): negative Serum uric acid: (normal 2.4-6.0 mg/dL. (female) and 3.4 - 7.0 mg/dL. (male). Individuals with laboratory results outside of the normal range will be excluded from further study procedures and will be ineligible to participate in further study procedures including being ineligible to be randomized or receive study drug.

To assess bone mass, a bone mineral density (BMD) by dual energy x-ray absorptiometry (DEXA) of the lumbar spine and bilateral hips will be performed. Additional inclusion and exclusion criterion are described below. Results from the screening visit will be reviewed by the medical monitoring team and investigators, who will make the final decision regarding the patient's eligibility for inclusion in the study.

RANDOMIZATION AND GROUP ASSIGNMENT Upon completion of the screening visit if the consenting soldier is found eligible for the study, the participant would then be randomized via computer generated block randomization performed by the research nurse coordinator. There will be a 1:1 randomization into either the placebo arm or the 20 mcg teriparatide treatment arm. The Pharmacist of Record would then record which study arm into which the patient was randomized, dispense the appropriate blinded medication (active study drug vs placebo) to the research nurse and store the assigned information securely using an encrypted data base. The injection pens will be blinded to the patient, the research nurse coordinator, and the staff at Ft. Jackson. If an emergency in patient care arises, any medical staff treating the patient can request un-blinding by calling the research team. The investigative team will be immediately informed of any such requests to ensure safety of the study subject.

INTERVENTION Following group assignment, the study participant will have a meeting with the research nurse to be instructed on care and handling of the medication. The participant will then directly observe the first administration of the medication to ensure safe and effective administration and remind the subject/participant to alternate injection sites such as the abdomen or leg as well as not injecting in same spot on the abdomen or leg each day to avoid bruising. Next the participant will be a given 28 tablets of 500 mg Calcium to take orally.

The participants will then leave Ft. Jackson and return home for convalescent leave. The participant will self-administer the mediation daily via injection pen and will receive a weekly call from the research nurse to ensure study medication compliance and monitor for any adverse events.

Upon return from 30 days of convalescent leave, participants will report back to Ft. Jackson and begin the reattachment process to their unit. At this time, the participant will have another peripheral venous blood draw to evaluate calcium level. Participants will then transition into the active rehabilitation phase of the study in which they will report daily to the physical therapy department on Ft. Jackson for treatment, per the standard of care.

During their scheduled reporting at physical therapy, participants will complete a training log of their previous day's activities. This will allow for a day-to-day tracking of physiologic load. They will continue to advance the training and activity as tolerated based on their pain and guidance from the physical therapist until the participant successfully completes the Army Combat Fitness Test (ACFT) which will qualify them for return to duty.

Once participants have matriculated through basic training, they will receive their initial duty station. Their military record, including physical profile (limited duty) status, new or recurrent bone stress injury diagnosis, the need to convene a medical discharge board or successful uninterrupted completion of their duty station will be monitored and recorded. To determine the long-term effects of the administration of teriparatide, study enrollees will be followed for 1-year post study drug year. this follow-up is to determine the incidence of drug-related side effects, injury recurrence and/or additional bone stress injury based on data from the participants' Electronic Medical Record. ;

Related Conditions & MeSH terms

• Fracture Healing
• Fractures, Bone
• Fractures, Stress
• Military Training
• Stress Fracture

• NCT number: NCT04533984
• Study type: Interventional
• Source: University of South Carolina
• Contact: F F Beattie, PhD
• Phone: 803-447-1589
• Email: pbeattie@mailbox.sc.edu
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: October 1, 2020
• Completion date: September 25, 2024